Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $47,072 | $78,592 | $46,826 | $72,832 |
| % Growth | -40.1% | 67.8% | -35.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $47,072 | $78,592 | $46,826 | $72,832 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $240,248 | $189,081 | $164,248 | $137,017 |
| G&A Expenses | $63,534 | $55,041 | $43,834 | $36,345 |
| SG&A Expenses | $63,534 | $55,041 | $43,834 | $36,345 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,925 | $0 | $0 | $0 |
| Operating Expenses | $308,707 | $244,122 | $208,082 | $173,362 |
| Operating Income | -$261,635 | -$165,530 | -$161,256 | -$100,530 |
| % Margin | -555.8% | -210.6% | -344.4% | -138% |
| Other Income/Exp. Net | $37,777 | $18,568 | $6,448 | $313 |
| Pre-Tax Income | -$223,858 | -$146,962 | -$154,808 | -$100,217 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$223,858 | -$146,962 | -$154,808 | -$100,217 |
| % Margin | -475.6% | -187% | -330.6% | -137.6% |
| EPS | -2.98 | -2.52 | -2.87 | -2.09 |
| % Growth | -18.3% | 12.2% | -37.3% | – |
| EPS Diluted | -2.98 | -2.52 | -2.87 | -2.09 |
| Weighted Avg Shares Out | 75,044 | 58,365 | 53,933 | 47,989 |
| Weighted Avg Shares Out Dil | 75,044 | 58,365 | 53,933 | 47,989 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38,026 | $18,764 | $6,624 | $488 |
| Interest Expense | $249 | $196 | $176 | $175 |
| Depreciation & Amortization | $7,373 | $3,565 | $2,977 | $2,397 |
| EBITDA | -$216,236 | -$143,201 | -$151,655 | -$97,645 |
| % Margin | -459.4% | -182.2% | -323.9% | -134.1% |